Skip to main content

Table 3 Summary of the most common (≥5%) adverse eventsa (ASaT population)

From: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

  Fosaprepitant regimen Control regimen
AE, n (% GI or colorectal cancers (n = 135) Lung cancer (n = 130) Breast cancer (n = 110) Gynecologic cancer (n = 81) GI or colorectal cancers (n = 132) Lung cancer (n = 124) Breast cancer (n = 121) Gynecologic cancer (n = 71)
Any 83 (61.5) 73 (56.2) 86 (78.2) 41 (50.6) 80 (60.6) 66 (53.2) 88 (72.7) 42 (59.2)
Neutropenia 2 (1.5) 7 (5.4) 27 (24.5) 3 (3.7) 1 (0.8) 5 (4.0) 23 (19.0) 5 (7.0)
Diarrhea 25 (18.5) 8 (6.2) 19 (17.3) 5 (6.2) 23 (17.4) 4 (3.2) 24 (19.8) 4 (5.6)
Fatigue 18 (13.3) 17 (13.1) 26 (23.6) 10 (12.3) 13 (9.8) 12 (9.7) 25 (20.7) 10 (14.1)
Constipation 18 (13.3) 7 (5.4) 12 (10.9) 8 (9.9) 10 (7.6) 10 (8.1) 20 (16.5) 8 (11.3)
Headache 11 (8.1) 4 (3.1) 12 (10.9) 2 (2.5) 12 (9.1) 3 (2.4) 16 (13.2) 2 (2.8)
Decreased appetite 11 (8.1) 5 (3.8) 5 (4.5) 5 (6.2) 11 (8.3) 7 (5.6) 10 (8.3) 3 (4.2)
Dysgeusia 4 (3.0) 3 (2.3) 9 (8.2) 2 (2.5) 7 (5.3) 0 13 (10.7) 1 (1.4)
Arthralgia 2 (1.5) 4 (3.1) 6 (5.5) 6 (7.4) 2 (1.5) 6 (4.8) 6 (5.0) 4 (5.6)
Peripheral neuropathy 10 (7.4) 1 (0.8) 0 1 (1.2) 5 (3.8) 0 2 (1.7) 4 (5.6)
Bone pain 0 0 8 (7.3) 0 1 (0.8) 3 (2.4) 6 (5.0) 0
Abdominal pain 8 (5.9) 2 (1.5) 2 (1.8) 1 (1.2) 6 (4.5) 1 (0.8) 3 (2.5) 3 (4.2)
Myalgia 1 (0.7) 3 (2.3) 4 (3.6) 4 (4.9) 2 (1.5) 4 (3.2) 6 (5.0) 7 (9.9)
Alopecia 2 (1.5) 2 (1.5) 5 (4.5) 2 (2.5) 3 (2.3) 5 (4.0) 13 (10.7) 4 (5.6)
Asthenia 6 (4.4) 7 (5.4) 3 (2.7) 2 (2.5) 9 (6.8) 3 (2.4) 1 (0.8) 1 (1.4)
Dizziness 2 (1.5) 2 (1.5) 5 (4.5) 3 (3.7) 2 (1.5) 2 (1.6) 7 (5.8) 0
Febrile neutropenia 1 (0.7) 1 (0.8) 5 (4.5) 2 (2.5) 0 3 (2.4) 7 (5.8) 0
Nausea 4 (3.0) 5 (3.8) 3 (2.7) 4 (4.9) 10 (7.6) 5 (4.0) 2 (1.7) 3 (4.2)
Paresthesia 6 (4.4) 0 0 0 8 (6.1) 0 0 1 (1.4)
Rash 2 (1.5) 1 (0.8) 4 (3.6) 1 (1.2) 0 3 (2.4) 6 (5.0) 0
Decreased neutrophil count 0 1 (0.8) 3 (2.7) 0 0 0 7 (5.8) 1 (1.4)
Stomatitis 3 (2.2) 1 (0.8) 1 (0.9) 1 (1.2) 2 (1.5) 1 (0.8) 10 (8.3) 0
Dyspnea 1 (0.7) 8 (6.2) 0 0 2 (1.5) 0 1 (0.8) 0
Musculoskeletal pain 0 1 (0.8) 3 (2.7) 1 (1.2) 0 3 (2.4) 5 (4.1) 7 (9.9)
  1. AE adverse event, ASaT all-subjects-as-treated, GI gastrointestinal
  2. aGrades 1 to 4 by maximum toxicity grade in subjects within either treatment arm